Table 3 Correlation between serum PIVKA-II levels and clinicopathological characteristics in HCC
Characteristics | N (%) | PIVKA-II (mAU/mL) Median (Interquartile range) | P value |
|---|---|---|---|
Age (year) | |||
<55 | 70 (41.67) | 290.90 (61.32–1474.00) | |
>55 | 98 (58.33) | 156.30 (59.87–1264.00) | 0.7477 |
Sex | |||
Male | 117 (69.64) | 172.40 (61.50–1212.00) | |
Female | 51 (30.36) | 243.60 (45.23–1559.00) | 0.6755 |
Tumor size | |||
<5 cm | 53 (31.55) | 127.00 (52.28–355.90) | |
>5 cm | 115 (68.45) | 440.60 (62.74–2000.00) | < 0.01 |
Tumor number | |||
Single | 137 (81.55) | 166.30 (46.55–1151.00) | |
Multiple | 31 (18.45) | 515.00 (109.80–6623.00) | 0.0143 |
Tumor stage | |||
I | 48 (28.57) | 62.41 (25.43–412.00) | |
II | 57 (33.93) | 174.30 (73.43–1059.00) | |
III | 26 (15.48) | 775.9 (159.79–2241.00) | |
IV | 37 (22.02) | 1854.00 (255.40–10,438.00) | < 0.01 |
Lymph node metastasis metastasis | |||
Yes | 42 (25.00) | 722.30 (162.00–2759.00) | |
No | 126 (75.00) | 147.40 (46.55–1086.00) | < 0.01 |
Distant metastasis | |||
Yes | 36 (21.43) | 1745.00 (558.30–10,342.00) | |
No | 132 (78.57) | 128.50 (44.04–710.90) | < 0.01 |
Gross type | |||
Nodular | 23 (13.69) | 328.20 (62.74–1854.00) | |
Massive | 93 (55.36) | 185.40 (68.05–1394.00) | |
Diffuse | 52 (30.95) | 163.90 (44.90–1150.00) | 0.6514 |
Differentiation degrees | |||
Well | 42 (25.00) | 60.91 (27.62–334.30) | |
Moderate | 64 (38.10) | 173.30 (49.39–1534.00) | |
Poor | 62 (36.90) | 565.10 (148.10–1886.00) | < 0.01 |
Complications | |||
Yes | 45 (26.79) | 713.40 (184.00–3232.00) | |
No | 123 (73.21) | 117.70 (42.34–1056.00) | < 0.01 |